Table 7.
Clinical studies analyzing therapies targeting apoptosis.
| Target | Molecule | Date | Protocol | Phase | Patients |
|---|---|---|---|---|---|
| CD95 | APG101 | ||||
| NCT01071837 | 02/2010–06/2015 | Combined with re-irradiation compared to re-irradiation alone | II | R | |
| Results (91 patients): PFS 2.5 months vs. 4.5 months (p = 0.0162; HR = 0.49); OS 11.5 months vs. 11.5 months; reirradation vs. reirradiation + APG101 [215] | |||||
| NCT03158389 | 05/2017–02/2020 | Molecularly Matched Targeted Therapies (APG101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib) combined with RT [71] | I/II | N without MGMT promoter methylation | |
| See Vismodegib | |||||
| DRD2/3 | ONC201 | ||||
| NCT02525692 | 08/2015–01/2020 | Monotherapy | II | R H3 K27M positive | |
| Results: (14 patients): OS 17 weeks; PFS 14 weeks [216] | |||||
| p53 | Gene therapy (SGT-53) | ||||
| NCT02340156 | 12/2014–03/2020 | Combined with TMZ | II | R | |
| Unpublished data | |||||
| p53-MDM2 | Idasanutlin (RG7388) | ||||
| NCT03158389 | 05/2017–02/2020 | Molecularly Matched Targeted Therapies (APG101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib) combined with RT [71] | I/II | N without MGMT promoter methylation | |
| See Vismodegib | |||||
| Bcl-2 | Gossypol | ||||
| NCT00540722 | 10/2007–03/2017 | Monotherapy | II | R | |
| Results (56 patients): PFS 1.87 months; OS = 5.9 months | |||||
| Farnesyl transferase | Tipifarnib | ||||
| NCT00050986 | 01/2003–08/2012 | Combined with TMZ | I/II | R | |
| No published results | |||||
| NCT00058097 | 04/2003–04/2013 | Combined with RT | II | N | |
| Results (28 patients): PFS 42 days; OS 234.5 days [217] | |||||
| NCT00005859 | 01/2003–06/2018 | Monotherapy | I/II | R | |
| Results (67 patients): PFS 8 vs. 6 weeks (p = 0.01) patients non- EIAED vs. patients EIAED [218] | |||||
| NCT00335764 | 04/2006–07/2018 | Sorafenib combined with erlotinib. tipifarnib or temsirolimus | I/II | R | |
| See Sorafenib | |||||
| Lonafarnib | |||||
| NCT00038493 | 06/2002–10/2018 | Combined with TMZ | II | R | |
| Unpublished data | |||||
R: recurrent GBM; N: newly diagnosed GBM; PFS: progression-free survival; PFS-6: 6-month survival; OS: overall sur-vival. In red, not significant comparative tests. In green, significant comparative tests. In italics, clinical trials listed in other tables (as mentioned). Results obtained from Clinicaltrials.com (accessed on 1 April 2020) and/or in cited references. Dates correspond to first posted and last update posted.